Nexalin Technology Participates in Congressional Roundtable Focused on Emerging Virtual Therapeutic Options for Opioid TreatmentGlobeNewsWire • 09/05/24
Nexalin Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TVAccesswire • 07/26/24
Nexalin Technology Selected to Join Industry Coalition: Breaking Barriers to Substance Use RecoveryGlobeNewsWire • 07/18/24
Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device for the Treatment of Alzheimer's and DementiaGlobeNewsWire • 06/20/24
Nexalin Technology and VolitionRX Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TVAccesswire • 06/14/24
Nexalin Technology Announces Regulatory Approval to Sell Nexalin's Gen-2, 15 mA Neurostimulation Device by the Brazilian Health Regulatory Agency (Anvisa)GlobeNewsWire • 06/13/24
Nexalin Technology to Present at the Spring MicroCap Rodeo Conference on June 6thGlobeNewsWire • 06/04/24
FDA Provides Feedback and Reaches Consensus on Nexalin's Design for Planned Anxiety and Insomnia Clinical Studies of its Gen-3 HALO Clarity™ Headset DeviceGlobeNewsWire • 06/03/24
Nexalin America Selected to Join the National Traumatic Brain Injury Registry Coalition to Propel TBI Awareness and Research EffortsGlobeNewsWire • 05/22/24
Nexalin Technology Regains Compliance with Nasdaq Continued Listing RequirementsGlobeNewsWire • 04/25/24
Nexalin Technology Awarded Key Patent Related to its Gen-3 HALO Clarity™, a Non-Invasive, Frequency-Based Deep-Brain Stimulation DeviceGlobeNewsWire • 04/04/24
Nexalin Technology's neurostimulation device shows promise in easing mTBI symptoms in veteransProactive Investors • 04/02/24
Nexalin Technology Announces the Appointment of Government Affairs Veteran William A. Hudson, Jr. to Military & Government Advisory BoardGlobeNewsWire • 04/02/24
Nexalin Technology Announces Positive Results of Clinical Study Validating its Gen-2 tACS Device for Reducing Pain Among Veterans with Mild Traumatic Brain Injury at University of California, San DiegoGlobeNewsWire • 03/28/24
Nexalin Technology Commences Sales of Gen-2 Neurostimulation Device to New Mental Health Center in Oman Dedicated to Nexalin's TechnologyGlobeNewsWire • 03/14/24
Nexalin Technology Announces Poster Presentation at “State of the Technology Meeting: Neurotrauma Diagnosis, Monitoring, and Assessment”GlobeNewsWire • 03/13/24
Nexalin Technology Announces Positive Results from Clinical Study of its Gen-2 tACS Device for Treating Adult Patients with Chronic InsomniaGlobeNewsWire • 03/06/24
Nexalin Technology Announces Regulatory Approval in Oman for Gen-2 Neurostimulation DeviceGlobeNewsWire • 02/08/24
Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device – the Transcranial Alternating Current Dynamic Frequency Stimulation (TACS) SystemGlobeNewsWire • 01/23/24